Genespire and SR-TIGET Show Durable Preclinical Efficacy ofLiver-Directed Gene Therapy for Methylmalonic Acidemia da Harry Fowler | Lug 8, 2026 | Notizie
Genespire raises €46.6 million (~$52 million) in a Series B round to advance its first pediatric in-vivo gene therapy into the clinic da Harry Fowler | Set 25, 2024 | Notizie
Genespire Presents Positive Preclinical Proof of Concept Data at the ASGCT Annual Meeting da Harry Fowler | Mag 9, 2024 | Notizie
Genespire Strengthens Management Team with Two Key Appointments da Harry Fowler | Apr 5, 2021 | Notizie
Genespire appoints Jörn Aldag as Chairman of the Board of Directors da Harry Fowler | Lug 2, 2020 | Notizie
